Why wait? The FDA stamps an ul­tra-fast OK on a HER2+ drug ex­pect­ed to cre­ate As­traZeneca's next block­buster fran­chise

The FDA isn’t play­ing any wait­ing games when it comes to hus­tling up a quick OK for a break­through can­cer drug.

In what has to be the fastest cul­mi­na­tion of one of the smoothest mul­ti-bil­lion dol­lar al­liances in bio­phar­ma his­to­ry, the agency stamped their seal of mar­ket­ing ap­proval on trastuzum­ab derux­te­can, a re­mark­able new drug now ready to mar­ket at As­traZeneca and their part­ners at Dai­ichi Sankyo.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN